Author:
De Camps Martinez Elmer R,Gonzalez Camila,Hassan Hamzah,Hassan Hafsa,Hassan Farooq
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. (2018). Accessed. April 16, 2018: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-combination-int....
2. Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade;Naidoo J;Oncologist,2017
3. Immune-related adverse events of checkpoint inhibitors;Ramos-Casals M;Nat Rev Dis Primers,2020
4. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature;Cappelli LC;Arthritis Care Res (Hoboken),2017
5. Immune checkpoint inhibitor-induced musculoskeletal manifestations;Angelopoulou F;Rheumatol Int,2021